Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Return on Sales (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Return on Sales data on record, last reported at 1.85% in Q4 2025.

  • For Q4 2025, Return on Sales rose 483.0% year-over-year to 1.85%; the TTM value through Dec 2025 reached 2.92%, up 4.0%, while the annual FY2025 figure was 2.92%, 4.0% up from the prior year.
  • Return on Sales reached 1.85% in Q4 2025 per CCCC's latest filing, up from 2.86% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.78% in Q4 2021 and bottomed at 13.48% in Q2 2023.
  • Average Return on Sales over 5 years is 4.99%, with a median of 3.27% recorded in 2021.
  • Peak YoY movement for Return on Sales: crashed -1204bps in 2022, then soared 1201bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 0.78% in 2021, then plummeted by -1544bps to 12.82% in 2022, then increased by 17bps to 10.66% in 2023, then skyrocketed by 37bps to 6.68% in 2024, then soared by 72bps to 1.85% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 1.85% in Q4 2025, 2.86% in Q3 2025, and 4.03% in Q2 2025.